Enterprise Value

2.386B

Cash

436.6M

Avg Qtr Burn

-59.98M

Short % of Float

14.57%

Insider Ownership

2.21%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Mirdametinib Details
NF1-associated Plexiform Neurofibromas, Cancer
No event data in pipeline

Approved

Quarterly sales

Nirogacestat Details
Cancer, Ovarian cancer, recurrent ovarian granulosa cell tumors

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1b

Data readout

Brimarafenib (BGB-3245) + panitumumab Details
Cancer, Colorectal cancer , Pancreatic cancer

Phase 1b

Data readout

Nirogacestat + teclistamab Details
Multiple myeloma, Cancer

Phase 1b

Data readout

Phase 1b

Data readout

Phase 1a

Initiation